Medicamen Biotech Approves Equity Allotment via Warrant Conversion
Medicamen Biotech Ltd 路 Others (Uncategorized) 路 23 Oct 2026, 5:31 pm
Medicamen Biotech Approves Equity Allotment via Warrant Conversion Medicamen Biotech Limited's Preferential Issue Committee approved the allotment of 5,00,000 equity shares upon conversion of equivalent fully convertible warrants on 23rd Oct'26. The shares were allotted to promoter group entity Shivalik Rasayan Limited at an issue price of Rs. 530 per share for cash, aggregating to Rs. 26.50 crore. Post-allotment, the company's paid-up equity share capital expanded to Rs. 14.06 crore, comprising 1,40,62,815 equity shares of face value Rs. 10 each.
Original exchange filing (PDF)
More announcements from Medicamen Biotech Ltd
- Medicamen Biotech Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. 路 13 Nov 2026
- Financial Results - Quarter and Half year ended on September 30, 2026 路 13 Nov 2026
- MEDICAMEN BIOTECH LIMITED has informed the Exchange about Board Meeting to be held on 13-Nov-2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the Half Yearly ended September 2026 . 路 13 Nov 2026
- MEDICAMEN BIOTECH LIMITED has informed the Exchange about Board Meeting to be held on 13-Nov-2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the Half Yearly ended September 2026 . 路 13 Nov 2026
- To consider and approve the financial results for the period ended September 30, 2026 路 13 Nov 2026
- Medicamen Biotech Ltd-has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/11/2026 ,inter alia, to consider and approve the unaudited financial .... 路 13 Nov 2026
- The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Shivalik Rasayan Ltd & Growel Remedies Ltd 路 26 Oct 2026
- Trading Plan under SEBI (PIT) Regulations 2015 - Mr Sanjay Bansal 路 30 Sept 2026
